NGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
NERVGEN PHARMA CORP.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 31, 2026
$1.54−0.05 (-3.14%)
Close on Oct 19, 2026
Nervgen Pharma statistics
Financials through Dec 31, 2025, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Nervgen Pharma | Industry median |
|---|---|---|
| Market Cap | C$175.02M | C$123.83M |
| Enterprise Value | C$152.95M | C$93.80M |
Income (trailing twelve months)
| Measure | Nervgen Pharma | Industry median |
|---|---|---|
| EPS (Diluted) | -0.61 CAD | -0.19 CAD |
Balance sheet
| Measure | Nervgen Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | C$22.07M | C$27.83M |
| Net Cash (Debt) | C$22.07M | C$27.83M |
| Net Cash Per Share | 0.28 CAD | 0.25 CAD |
| Working Capital | C$3.07M | C$25.22M |
Financial position
| Measure | Nervgen Pharma | Industry median |
|---|---|---|
| Current Ratio | 1.16 | 2.65 |
| Quick Ratio | 1.12 | 1.40 |
Cash flow (trailing twelve months)
| Measure | Nervgen Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -C$19.50M | -C$8.69M |
Dividends and yields
| Measure | Nervgen Pharma | Industry median |
|---|---|---|
| Buyback Yield | -9.65% | -9.44% |
| Shareholder Yield | -9.65% | -9.44% |
Shares
| Measure | Nervgen Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 79,649,300 | 74,643,400 |
| Shares Change (YoY) | 7.44% | 18.0% |
| Float | 79,649,300 | 74,292,200 |
| Shares Held by Insiders | 0.00% | 0.00% |
| Shares Held by Institutions | 15.1% | 9.14% |
Scores
| Measure | Nervgen Pharma | Industry median |
|---|---|---|
| Altman Z-Score | -3.37 | -0.68 |
Calculated by StockData from Nervgen Pharma's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.